Anti-angiogenic compounds

US9975860B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9975860-B2
Application numberUS-201515111865-A
CountryUS
Kind codeB2
Filing dateJan 15, 2015
Priority dateJan 17, 2014
Publication dateMay 22, 2018
Grant dateMay 22, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds and compositions are described which are useful especially for treatment of angiogenesis-related diseases or disorders such as neovascularisation of the eye, age-related macular degeneration, diabetic retinopathy or cancer.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for the treatment of an angiogenesis related disease or disorder comprising the step of administering a compound of the formula or a salt thereof. 2. The method as claimed in claim 1 , wherein the angiogenesis-related disease or disorder is associated with neovascularisation of the eye. 3. The method as claimed in claim 1 , wherein the angiogenesis-related disease or disorder is associated with blindness. 4. The method as claimed in claim 1 , wherein the angiogenesis-related disease or disorder is age-related macular degeneration or diabetic retinopathy. 5. The method as claimed in claim 4 , wherein the age-related macular degeneration is wet age-related macular degeneration. 6. The method as claimed in claim 1 , wherein the angiogenesis-related disease or disorder is cancer. 7. The method as claimed in claim 6 , wherein the cancer is a solid tumour forming cancer. 8. The method as claimed in claim 6 , wherein the cancer is colorectal cancer. 9. The method as claimed in claim 6 , wherein the cancer is oesophageal cancer. 10. The method as claimed in claim 6 , wherein the cancer is breast cancer.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

  • C07D241/12Primary

    with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

  • linked by a carbon chain containing only aliphatic carbon atoms · CPC title

  • Ophthalmic agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9975860B2 cover?
Compounds and compositions are described which are useful especially for treatment of angiogenesis-related diseases or disorders such as neovascularisation of the eye, age-related macular degeneration, diabetic retinopathy or cancer.
Who is the assignee on this patent?
Univ College Dublin—National Univ Of Ireland Dublin, Provost Fellows Found Scholars & Other Members Board College Holy & Und, Univ College Dublin Nat Univ Ireland Dublin, and 1 more
What technology area does this patent fall under?
Primary CPC classification C07D241/12. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).